Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Cancer·2026
Same author

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Cancer·2025
Same author

Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.

Leukemia research·2025
Same author

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Blood advances·2025
Same author

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.

Scientific reports·2024

Related Experiment Video

Updated: May 16, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

New strategies for stem cell mobilization.

Roberto M Lemoli1

  • 1Department of Hematology and Oncological Sciences "L. e A. Seràgnoli", Institute of Hematology, University of Bologna.

Mediterranean Journal of Hematology and Infectious Diseases
|November 22, 2012
PubMed
Summary

Plerixafor effectively mobilizes hematopoietic stem cells in patients undergoing autologous stem cell transplantation who typically fail to mobilize sufficient cells. This approach enhances stem cell collection for cancer treatment.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Mobilized peripheral blood stem cells (PBSCs) are crucial for autologous stem cell transplantation (ASCT).
  • Standard mobilization strategies using cytokines or chemotherapy (chemomobilization) are insufficient for a significant number of cancer patients.
  • Poor mobilization hinders ASCT, necessitating alternative approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of plerixafor in enhancing PBSC mobilization.
  • To assess plerixafor's role in patients with poor mobilization after standard treatment.
  • To explore the preemptive use of plerixafor in hard-to-mobilize patients.

Main Methods:

  • Plerixafor, a CXCR4 antagonist, was administered to disrupt the CXCR4-CXCL12 interaction.

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

Related Experiment Videos

Last Updated: May 16, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

  • This mechanism promotes the release of CD34(+) hematopoietic stem cells from bone marrow to peripheral blood.
  • Combination therapy with chemotherapy and G-CSF was investigated in poor mobilizers.

    • Main Results:

    • Plerixafor significantly increased circulating CD34(+) cells, often by several folds.
    • The majority of patients identified as 'poor mobilizers' achieved successful stem cell collection with plerixafor.
    • Addition of plerixafor to chemotherapy plus G-CSF demonstrated safety and effectiveness in patients with low CD34(+) counts or poor initial yields.

    Conclusions:

    • Plerixafor is a safe and effective option for enhancing PBSC mobilization, particularly in patients who mobilize poorly.
    • Its mechanism of action makes it suitable for preemptive use in individuals predicted to be difficult to mobilize.
    • Plerixafor improves the success rate of ASCT by ensuring adequate stem cell collection.